Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.

Arterioscler Thromb Vasc Biol 2006 Jan 10;26(1):182-8. Epub 2005 Nov 10.

Division of General Internal Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Objective: The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn).

Methods And Results: Sixty nondiabetic adults with low HDL-C and MetSyn were randomized to PIO or matching placebo for 12 weeks. PIO increased HDL-C by 15% and 14% at 6 and 12 weeks, respectively, compared with placebo (P<0.001). Changes in HDL-C were correlated to changes in adiponectin (r=0.34; P=0.01) but not to changes in insulin resistance. PIO did not affect serum triglycerides or low-density lipoprotein (LDL) cholesterol concentrations but reduced the number of small LDL particles by 18% (P<0.001). PIO reduced median C-reactive protein levels by 31% (P<0.001) and mean resistin levels by 10% (P=0.02) while increasing mean serum levels of adiponectin by 111% (P<0.001) compared with placebo. PIO did not affect weight and modestly decreased insulin resistance.

Conclusions: In nondiabetic patients with low HDL-C and MetSyn, PIO significantly raised HDL-C and favorably affected lipoprotein particle size, markers of inflammation, and adipokines without changes in triglycerides, LDL-C, or weight. These results suggest that PIO has direct effects on HDL, which may contribute to its antiatherogenic effects.

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.ATV.0000195790.24531.4fDOI Listing
January 2006
11 Reads

Publication Analysis

Top Keywords

metabolic syndrome
8
patients metabolic
8
nondiabetic patients
8
effects pioglitazone
8
nondiabetic adults
4
adults low
4
low hdl-c
4
sixty nondiabetic
4
hdl-c metsyn
4
syndrome metsynmethods
4
lipoprotein cholesterol
4
high-density lipoprotein
4
hdl-c metabolic
4
metabolic parameters
4
parameters nondiabetic
4
metsynmethods sixty
4
randomized pio
4
15% 14%
4
hdl-c 15%
4
14% weeks
4

References

(Supplied by CrossRef)

Clin Lab 2002

Similar Publications